Bladder cancer most commonly begins in the inner lining of the bladder (the urothelium). In more advanced cases, it may grow into the muscular wall and potentially beyond. Its most common first sign is painless blood in the urine (haematuria), which occurs in approximately 80% of cases. Some patients also experience irritative voiding symptoms such as urinary urgency, frequency, or discomfort during urination.
MBBS (NUS)|MRCS (Edin.)|MMed Surgery (NUS)|FAMS (Urology)
Finding blood in your urine can be concerning. A bladder cancer diagnosis adds another layer of complexity, changing how you think about something as simple as going to the bathroom.
Between that first moment of concern and a clear plan forward, there is a structured clinical path. A specialist consultation connects your symptoms to an accurate diagnosis, appropriate treatment, and a plan to support your urinary health and quality of life.
Many people first notice pink or red-tinged urine, or find themselves needing to urinate far more often than usual. These symptoms can also result from unrelated conditions, such as urinary tract infections, benign prostate changes, or bladder stones.
That overlap is precisely why professional evaluation matters. A urologist follows a structured diagnostic pathway to determine what is actually happening inside your bladder.
The process begins with a detailed conversation about your symptoms, medical history, and any relevant exposures. Your urologist may also order a urinalysis, a laboratory test that examines your urine for blood cells and signs of infection, and, where indicated, a separate urine cytology, which looks for abnormal or cancerous cells under a microscope.
This helps narrow down possible causes and determines whether further investigation is needed.
If initial findings raise concern, your urologist may recommend a CT urogram. This imaging study uses contrast dye to create detailed pictures of your urinary tract, including your kidneys, ureters, and bladder. It can reveal tumours, blockages, or structural abnormalities not visible through a basic examination.
The most definitive step is cystoscopy. During this procedure, a thin camera called a cystoscope is passed through the urethra to directly visualise the interior surface of your bladder. A flexible cystoscope is typically used for initial diagnostic examination under local anaesthesia, while a rigid cystoscope, used under general anaesthesia, is employed when a biopsy or tumour removal is required. If any abnormal growths are seen, your urologist will take a tissue sample. For most cases, this is performed through a procedure called transurethral resection of bladder tumour (TURBT), which is both diagnostic and, for non-muscle-invasive disease, often therapeutic, removing the tumour while simultaneously obtaining tissue for analysis.
A definitive diagnosis of bladder cancer requires this tissue sampling. No imaging or urine test can replace the information gained from examining actual bladder tissue under a microscope. This confirms the type of cancer, its grade, and how deeply it has grown.
Because symptoms like blood in the urine look the same whether the cause is benign or malignant, professional evaluation is essential.
Understanding the biological process behind bladder cancer can help put questions about cause into perspective.
Your bladder is lined with specialised cells called urothelial cells, which are in constant contact with urine carrying filtered waste products and chemical metabolites. Over time, repeated exposure to certain harmful substances can damage the DNA within these cells. When that damage accumulates and the body’s repair mechanisms fail, cells may begin to grow and divide in an uncontrolled way. This process is known as malignant transformation, or carcinogenesis.
Tobacco use is the single most significant modifiable risk factor, responsible for approximately half of all bladder cancer cases and associated with a three to four times higher risk compared with non-smokers. When you smoke, cancer-causing chemicals — particularly aromatic amines — are absorbed from the lungs into your blood, filtered by your kidneys, and concentrated in your urine. The lining of your bladder is repeatedly exposed to these harmful metabolites, sometimes over decades.
Occupational chemical exposure is another well-documented risk. Workers in industries involving dyes, rubber, leather, textiles, and certain paints may encounter aromatic amines, chemical compounds linked to an increased risk of urothelial cancer after prolonged exposure.
Chronic bladder inflammation from recurrent infections, long-term catheter use, or bladder stones can also contribute. Persistent irritation of the bladder lining may accelerate the cycle of cell damage and repair that can lead to abnormal cell growth.
Genetic predisposition plays a role in some patients. A family history of bladder cancer, or inherited genetic variations affecting how your body processes certain toxins, may increase your susceptibility.
In some patients, no single identifiable cause can be determined. This reflects the complex, multifactorial nature of cancer biology and should not be a source of guilt or additional alarm.
The specific type of cancer cell involved and how far the disease has spread are the two factors that most directly shape your treatment plan.
The most common bladder cancers are urothelial carcinomas, sometimes called transitional cell carcinomas, which arise from the cells lining the inside of the bladder. This is the most common subtype in Singapore and globally.
Less frequently, bladder cancer may present as:
Each subtype may respond differently to treatment, which is why accurate identification through tissue biopsy is critical.
Non-muscle-invasive bladder cancer is confined to the inner lining of the bladder or the connective tissue just beneath it. The tumour has not grown into the thick muscular wall, known as the detrusor muscle. NMIBC includes several subtypes — including papillary tumours (Ta, T1) and carcinoma in situ (CIS), a flat, high-grade lesion that, despite being non-invasive, carries a significant risk of progression.
Muscle-invasive bladder cancer means the tumour has penetrated into the detrusor muscle. Deeper invasion increases the potential for the cancer to spread.
Metastatic bladder cancer indicates the disease has moved beyond the bladder, reaching nearby lymph nodes, bones, lungs, or other organs.
Doctors use the TNM staging system to classify the extent of disease:
Grading describes how abnormal the cancer cells appear under a microscope. Higher-grade tumours tend to grow and spread more aggressively. These classifications directly determine which treatments are appropriate, how intensive the approach should be, and what follow-up surveillance is needed.
It is easy to explain away urinary symptoms. You might assume blood in your urine is just an infection, or that needing to urinate more often is simply part of getting older. In many cases, those explanations may be correct. But there are situations where self-reassurance becomes a genuine risk.
Painless haematuria (blood in your urine without any accompanying discomfort) is a recognised warning sign that warrants timely urological assessment. Because it does not hurt, many people delay seeking advice, assuming it will resolve on its own.
During that time, a potentially manageable condition may progress to a stage requiring more extensive intervention. Early-stage disease confined to the bladder lining has a different treatment landscape compared to cancer that has invaded the muscle wall or spread to distant organs.
Self-directed measures do not address the underlying problem. The appropriate first step is to consult your GP, who can arrange prompt referral to a urologist for definitive investigation — typically cystoscopy and upper tract imaging.
If you notice blood in your urine or experience persistent, unexplained changes in urinary frequency, a consultation with your doctor is the appropriate next step. Pelvic discomfort alongside these symptoms may warrant additional investigation.
Painless haematuria is a recognised warning sign that warrants timely urological assessment to exclude or confirm malignancy and determine an appropriate clinical pathway.
The treatment your urologist recommends depends on the clinical stage and grade of your disease at diagnosis. Each decision is guided by what the tissue biopsy reveals, how deeply the tumour has grown, and your overall health profile.
When bladder cancer is confined to the inner lining of your bladder, the primary clinical goal is to remove the tumour completely and reduce the chance of recurrence.
The standard approach involves transurethral resection, an endoscopic technique where the urologist accesses the tumour through the urethra without any external incisions.
Following resection, your urologist may recommend intravesical therapy, which involves placing medication directly into the bladder through a catheter. The two main types of intravesical agents are immunotherapy (most commonly BCG, which stimulates an immune response against cancer cells) and chemotherapy agents (such as mitomycin C or gemcitabine, which target remaining tumour cells directly). The specific agent and treatment schedule depend on your individual risk profile.
Non-muscle-invasive bladder cancer carries a significant and well-documented recurrence risk — ranging from around 20% for low-risk disease to as high as 90% in high-risk cases within one to two years of TURBT. Structured follow-up with regular cystoscopy is therefore a necessary part of your care.
When the disease has grown into the muscular wall of the bladder, organ-preserving strategies may no longer be sufficient to control the cancer effectively.
The standard of care at this stage often involves radical cystectomy, the surgical removal of the bladder. In men, radical cystectomy typically includes the removal of the prostate gland and seminal vesicles as part of the standard procedure. In women, the uterus, ovaries, and part of the vaginal wall may also be removed depending on the extent of disease. After bladder removal, your surgeon will create an alternative pathway for urine to leave your body, called urinary diversion.
Cisplatin-based chemotherapy is strongly recommended before surgery (neoadjuvant chemotherapy) to target microscopic spread and improve survival outcomes. For those who did not receive neoadjuvant therapy and have high-risk pathological features, adjuvant chemotherapy or immunotherapy may be offered after surgery.
In select cases, a bladder-preserving approach combining chemotherapy and radiation therapy may be considered. This is not suitable for every patient, and the decision involves a detailed discussion about potential risks, likelihood of success, and functional outcomes. Drawing on his specialisation in kidney, bladder, and prostate conditions, Dr Azhari guides patients through these complex treatment choices with a focus on balancing disease control with long-term quality of life.
When bladder cancer has spread beyond the bladder to lymph nodes, bones, lungs, or other organs, the focus of treatment shifts. The primary goals become systemic disease control, symptom management, and quality-of-life preservation.
Platinum-based chemotherapy regimens are a foundational part of systemic treatment for advanced bladder cancer, targeting rapidly dividing cancer cells throughout the body. For patients who are not candidates for platinum-based therapy, or whose disease progresses despite it, immunotherapy agents offer another avenue. These medications may help your immune system recognise and attack cancer cells.
Treatment response varies based on individual biological factors, including the molecular characteristics of the tumour itself. Your oncology and urology team will monitor your response and adjust the approach as needed.
Treatment at this stage aims to use available tools to manage the disease, maintain comfort, and support quality of life.
A structured urological consultation in Singapore can clarify stage-specific treatment pathways, from bladder-preserving resection to systemic therapy, enabling informed clinical decision-making.
Specialist-guided treatment for bladder cancer works toward several key clinical objectives. Understanding these goals can help you feel more informed in the decisions being made about your care.
The primary goals include:
For patients with more advanced disease, the goals may centre on slowing disease progression, controlling symptoms, and supporting daily function.
No two patients are biologically identical. Even when the same treatment protocol is applied, individual responses can differ based on tumour biology, overall health, immune function, and other factors. Your specialist will discuss this with you openly.
Every treatment pathway carries potential risks. These may include:
Dr Azhari’s approach includes a transparent discussion of these risks during the consultation process. With more than 15 years of clinical practice across kidney, bladder, and prostate conditions, he ensures you understand both the intended benefits and the realistic limitations of each option. Treatment decisions are made collaboratively, based on a thorough risk-benefit analysis that accounts for your individual circumstances.
Because your bladder’s inner lining is constantly exposed to substances filtered from your bloodstream, certain lifestyle choices can meaningfully influence your risk.
Smoking cessation is the single most impactful step you can take. Stopping tobacco use reduces the concentration of carcinogens passing through your urinary tract. The benefit increases the longer you remain smoke-free, though risk may not return to baseline levels.
Reducing occupational chemical exposure is also important. If your work involves contact with industrial dyes, rubber chemicals, or aromatic amines, following workplace safety protocols and using protective equipment can lower your exposure over time. Discuss any occupational concerns with your doctor, as they may recommend earlier or more frequent screening.
Staying well hydrated supports regular urination, which may help flush potential irritants from the bladder more efficiently. While hydration alone is not a proven prevention strategy, it is a reasonable habit to maintain alongside other measures.
If you have a personal history of bladder cancer, a strong family history, or significant occupational exposure, your urologist may recommend periodic screening even in the absence of symptoms. Early detection of recurrence or new disease is associated with more manageable treatment options.
The Limits of Prevention
Genetic susceptibility and certain biological predispositions cannot be fully eliminated through lifestyle changes alone. Prevention reduces risk; it does not guarantee that bladder cancer will never develop. Maintaining regular health check-ups and staying attentive to changes in your urinary habits remain your most practical defences.
No. Blood in the urine, called haematuria, can result from infections, kidney stones, benign prostate enlargement, or even vigorous exercise. It should always be evaluated by a specialist to rule out serious causes, including cancer.
Recurrence rates depend on the type, stage, and grade of the original tumour. Non-muscle-invasive bladder cancer has a well-documented tendency to recur, which is why regular surveillance cystoscopy is a standard part of follow-up care.
Not necessarily. Many early-stage cases are managed with endoscopic techniques that preserve the bladder. Bladder removal is typically considered when the cancer has invaded the muscular wall and organ preservation is no longer clinically sufficient.
The older term ‘superficial’ has largely been replaced in clinical practice by more precise staging. Early-stage disease includes tumours confined to the bladder lining (Ta) or those that have invaded the layer beneath the lining (T1), as well as flat high-grade lesions (carcinoma in situ). Each carries different risks and treatment implications. ‘Invasive’ refers to cancer that has grown into the deeper muscle wall of the bladder (T2 or beyond).
Yes. If untreated or inadequately managed, bladder cancer can spread to lymph nodes, bones, lungs, and other organs. This is referred to as metastatic disease and requires systemic treatment.
From initial consultation through cystoscopy and biopsy, results are typically available within one to two weeks, though the timeline varies. Your urologist will prioritise efficient evaluation to minimise delays.
Most cases are not directly inherited. Having a close family member with bladder cancer may slightly increase your risk. Certain genetic variations can also affect how your body handles carcinogens, potentially raising susceptibility.
Yes. Depending on the stage, treatment may include intravesical therapy, systemic chemotherapy, immunotherapy, or radiation therapy. Dr Azhari’s clinical experience across a wide range of bladder conditions allows him to guide patients toward an appropriate option for their individual situation.
Follow-up typically includes regular cystoscopy examinations, urine tests, and periodic imaging. The frequency of these appointments decreases over time if no recurrence is detected, but long-term monitoring remains important.
It can. If a tumour blocks the flow of urine from the kidneys to the bladder, it may cause kidney swelling, known as hydronephrosis, and impair kidney function. This is one reason why timely diagnosis and treatment matter.
Completing active treatment is a significant milestone, but long-term bladder health depends on consistent follow-up. This includes scheduled cystoscopy examinations, imaging when indicated, and ongoing attention to urinary symptoms.
Clinical success is not a single event. It is the sustained stability of your bladder and urinary tract, maintained through a partnership between you and your specialist. Staying engaged with your surveillance schedule and adopting evidence-based lifestyle habits supports your ongoing urological health.
Structured, long-term urological follow-up with Dr Azhari in Singapore supports recurrence monitoring, functional recovery, and ongoing quality of life through individualised surveillance and evidence-based care planning.
With more than 15 years experience as a certified Urologist, Dr Nor Azhari specializes in treating a wide range of kidney, bladder and prostate conditions as well as disorders of the male reproductive organs.
He offers minimally invasive treatment options and provides same-day appointments for convenience.
For urgent or same day appointment requests, please call our hotline.
Mount Elizabeth Novena Specialist Centre
38 Irrawaddy Road
#08-41 Singapore 329563
Mount Alvernia Hospital
820 Thomson Road Medical Centre Block A #05-03 Singapore 574623